Phase I study of ABT-199 (GDC-0199) in patients with relapsed/refractory non-hodgkin lymphoma: Responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses

Clinical Advances in Hematology and Oncology

Volumn 12, Issue 8, 2014, Pages 18-19

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN BCL 2; VENETOCLAX; 4-(4-((2-(4-CHLOROPHENYL)-4,4-DIMETHYLCYCLOHEX-1-EN-1-YL)METHYL)PIPERAZIN-1-YL)-N-((3-NITRO-4-((TETRAHYDRO-2H-PYRAN-4-YLMETHYL)AMINO)PHENYL)SULFONYL)-2-(1H-PYRROLO(2,3-B)PYRIDIN-5-YLOXY)BENZAMIDE; ANTINEOPLASTIC AGENT; FUSED HETEROCYCLIC RINGS; SULFONAMIDE;

B CELL LYMPHOMA; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; FOLLICULAR LYMPHOMA; HUMAN; LYMPHADENOPATHY; NEUTROPENIA; NONHODGKIN LYMPHOMA; NOTE; WALDENSTROEM MACROGLOBULINEMIA; AGED; ANTAGONISTS AND INHIBITORS; LYMPHOMA, FOLLICULAR; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; PHASE 1 CLINICAL TRIAL (TOPIC);

AGED; ANTINEOPLASTIC AGENTS; BICYCLO COMPOUNDS, HETEROCYCLIC; CLINICAL TRIALS, PHASE I AS TOPIC; HUMANS; LYMPHOMA, FOLLICULAR; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; PROTO-ONCOGENE PROTEINS C-BCL-2; SULFONAMIDES;

EID: 84941119772     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (2)

1. Rabkin CS, Hirt C, Janz S, Dölken G. t(14;18) Translocations and risk of follicular lymphoma. J Natl Cancer Inst Monogr. 2008;2008(39):48-51.
2. Davids MS, Seymour JF, Gerecitano JF, et al. Phase I study of ABT-199 (GDC-0199) in patients with relapsed/refractory non-Hodgkin lymphoma: responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses [EHA abstract S1348]. Haematologica. 2014;99(suppl 1):525.